Teva Pharmaceutical Industries (TEVA) R&D In Process: 2010-2017
Historic R&D In Process for Teva Pharmaceutical Industries (TEVA) over the last 1 years, with Sep 2017 value amounting to $175.0 million.
- Teva Pharmaceutical Industries' R&D In Process fell 30.56% to $175.0 million in Q3 2017 from the same period last year, while for Sep 2017 it was $461.0 million, marking a year-over-year increase of 60.07%. This contributed to the annual value of $5.0 million for FY2013, which is 93.15% down from last year.
- Per Teva Pharmaceutical Industries' latest filing, its R&D In Process stood at $175.0 million for Q3 2017, which was down 30.56% from $252.0 million recorded in Q3 2016.
- In the past 5 years, Teva Pharmaceutical Industries' R&D In Process ranged from a high of $252.0 million in Q3 2016 and a low of $2.0 million during Q4 2013.
- Over the past 3 years, Teva Pharmaceutical Industries' median R&D In Process value was $99.5 million (recorded in 2015), while the average stood at $115.2 million.
- Data for Teva Pharmaceutical Industries' R&D In Process shows a maximum YoY slumped of 97.06% (in 2013) over the last 5 years.
- Teva Pharmaceutical Industries' R&D In Process (Quarterly) stood at $2.0 million in 2013, then reached $24.0 million in 2015, then reached $252.0 million in 2016, then crashed by 30.56% to $175.0 million in 2017.
- Its R&D In Process stands at $175.0 million for Q3 2017, versus $252.0 million for Q3 2016 and $10.0 million for Q1 2016.